The 2017 World Health Organization classification of tumors of the pituitary gland: a summary

The 4th edition of the World Health Organization (WHO) classification of endocrine tumors has been recently released. In this new edition, major changes are recommended in several areas of the classification of tumors of the anterior pituitary gland (adenophypophysis). The scope of the present manuscript is to summarize these recommended changes, emphasizing a few significant topics. These changes include the following: (1) a novel approach for classifying pituitary neuroendocrine tumors according to pituitary adenohypophyseal cell lineages; (2) changes to the histological grading of pituitary neuroendocrine tumors with the elimination of the term “atypical adenoma;” and (3) introduction of new entities like the pituitary blastoma and re-definition of old entities like the null-cell adenoma. This new classification is very practical and mostly based on immunohistochemistry for pituitary hormones, pituitary-specific transcription factors, and other immunohistochemical markers commonly used in pathology practice, not requiring routine ultrastructural analysis of the tumors. Evaluation of tumor proliferation potential, by mitotic count and Ki-67 labeling index, and tumor invasion is strongly recommended on individual case basis to identify clinically aggressive adenomas. In addition, the classification offers the treating clinical team information on tumor prognosis by identifying specific variants of adenomas associated with an elevated risk for recurrence. Changes in the classification of non-neuroendocrine tumors are also proposed, in particular those tumors arising in the posterior pituitary including pituicytoma, granular cell tumor of the posterior pituitary, and spindle cell oncocytoma. These changes endorse those previously published in the 2016 WHO classification of CNS tumors. Other tumors arising in the sellar region are also reviewed in detail including craniopharyngiomas, mesenchymal and stromal tumors, germ cell tumors, and hematopoietic tumors. It is hoped that the 2017 WHO classification of pituitary tumors will establish more biologically and clinically uniform groups of tumors, make it possible for practicing pathologists to better diagnose these tumors, and contribute to our understanding of clinical outcomes for patients harboring pituitary tumors.

[1]  J. Sheehan,et al.  Silent corticotroph adenomas after stereotactic radiosurgery: a case-control study. , 2014, International journal of radiation oncology, biology, physics.

[2]  T. Sano,et al.  Immunoreactive luteinizing hormone in functioning corticotroph adenomas of the pituitary , 1990, Virchows Archiv A.

[3]  J. Lupski,et al.  Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study , 2016, Acta Neuropathologica Communications.

[4]  E. Laws,et al.  Double Pituitary Lesions in Three Patients with Cushing's Disease , 2000, Pituitary.

[5]  A. Wierinckx,et al.  Expression of estrogen receptor alpha is associated with prolactin pituitary tumor prognosis and supports the sex-related difference in tumor growth. , 2015, European journal of endocrinology.

[6]  Erratum: Histological criteria for atypical pituitary adenomas – data from the German pituitary adenoma registry suggests modifications , 2016, Acta neuropathologica communications.

[7]  E. Chang,et al.  A comprehensive long-term retrospective analysis of silent corticotrophic adenomas vs hormone-negative adenomas. , 2013, Neurosurgery.

[8]  E. Dursun,et al.  Incidence, hormonal distribution and postoperative follow up of atypical pituitary adenomas. , 2013, Turkish neurosurgery.

[9]  T. Sano,et al.  Immunohistochemical heterogeneity within clinically nonfunctioning pituitary adenomas , 1995, Endocrine pathology.

[10]  W. Olszewski,et al.  Double, Synchronous Pituitary Adenomas Causing Acromegaly and Cushing’s Disease. A Case Report and Review of Literature , 2013, Endocrine Pathology.

[11]  P. Maeder,et al.  Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations , 2014, Acta Neuropathologica.

[12]  R. Lloyd,et al.  Transcription factors in normal and neoplastic pituitary tissues , 1997, Microscopy research and technique.

[13]  J. Lupski,et al.  Germline or somatic GPR101 duplication leads to X-linked acrogigantism: a clinico-pathological and genetic study , 2016, Acta neuropathologica communications.

[14]  S. Coons,et al.  Cytokeratin CK 7 and CK 20 expression in pituitary adenomas , 2005, Endocrine pathology.

[15]  M. Korbonits,et al.  Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. , 2014, European journal of endocrinology.

[16]  B. Scheithauer,et al.  Pituitary blastoma: a unique embryonal tumor , 2012, Pituitary.

[17]  M. Vance,et al.  Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria. , 2001, The Journal of clinical endocrinology and metabolism.

[18]  Odelia Cooper.  Silent corticotroph adenomas , 2015, Pituitary.

[19]  L. Cavallo,et al.  Atypical pituitary adenomas: clinical characteristics and role of ki-67 and p53 in prognostic and therapeutic evaluation. A series of 50 patients , 2017, Neurosurgical Review.

[20]  B. Scheithauer,et al.  Crooke's Cell Adenoma of the Pituitary: An Aggressive Variant of Corticotroph Adenoma , 2003, The American journal of surgical pathology.

[21]  A. R.,et al.  Review of literature , 1969, American Potato Journal.

[22]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[23]  A. Tischler,et al.  The Adrenal Medulla and Extra-adrenal Paraganglia: Then and Now , 2014, Endocrine pathology.

[24]  Kathleen M. Scully,et al.  Pituitary Development: Regulatory Codes in Mammalian Organogenesis , 2002, Science.

[25]  Shereen Ezzat,et al.  Expression of Ki-67, PTTG1, FGFR4, and SSTR 2, 3, and 5 in nonfunctioning pituitary adenomas: a high throughput TMA, immunohistochemical study. , 2012, The Journal of clinical endocrinology and metabolism.

[26]  A. Kajdacsy-Balla,et al.  Steroidogenic Factor 1, Pit-1, and Adrenocorticotropic Hormone: A Rational Starting Place for the Immunohistochemical Characterization of Pituitary Adenoma. , 2017, Archives of pathology & laboratory medicine.

[27]  Ozgur Mete,et al.  Spindle Cell Oncocytomas and Granular Cell Tumors of the Pituitary Are Variants of Pituicytoma , 2013, The American journal of surgical pathology.

[28]  S. Asa,et al.  The Complementary Role of Transcription Factors in the Accurate Diagnosis of Clinically Nonfunctioning Pituitary Adenomas , 2015, Endocrine Pathology.

[29]  B. Scheithauer,et al.  Atypical, invasive, recurring Crooke cell adenoma of the pituitary , 2012, Hormones.

[30]  G. Sassolas,et al.  Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance , 2005, Acta Neurochirurgica.

[31]  C. Stratakis,et al.  Succinate dehydrogenase (SDHx) mutations in pituitary tumors: could this be a new role for mitochondrial complex II and/or Krebs cycle defects? , 2012, Endocrine-related cancer.

[32]  D. Figarella-Branger,et al.  Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment , 2012, Clinical endocrinology.

[33]  R. Osamura,et al.  Expression of GATA-2 in Human Pituitary Adenomas , 2002, Modern Pathology.

[34]  Tarik Tihan,et al.  Thyroid Transcription Factor 1 Expression in Sellar Tumors: A Histogenetic Marker? , 2009, Journal of neuropathology and experimental neurology.

[35]  S. Asa,et al.  Cell-specific expression of estrogen receptor in the human pituitary and its adenomas. , 1995, The Journal of clinical endocrinology and metabolism.

[36]  E. Laws,et al.  Predictors of aggressive clinical phenotype among immunohistochemically confirmed atypical adenomas , 2016, Journal of Clinical Neuroscience.

[37]  Robert Kiss,et al.  Computer-assisted microscope analysis of feulgen-stained nuclei in gonadotroph adenomas and null-cell adenomas of the pituitary gland , 1997, Endocrine pathology.

[38]  G. Kaltsas,et al.  Aggressive Pituitary Tumors , 2015, Neuroendocrinology.

[39]  R. Osamura,et al.  Application of catalyzed signal amplification in immunodetection of gonadotropin subunits in clinically nonfunctioning pituitary adenomas. , 1996, American journal of clinical pathology.

[40]  E. Oldfield,et al.  Multiple pituitary adenomas in Cushing's disease. , 2000, Journal of neurosurgery.

[41]  G. Kontogeorgos,et al.  The gonadotroph origin of null cell adenomas. , 2016, Hormones.

[42]  G. Maira,et al.  Typical and Atypical Pituitary Adenomas: A Single-Center Analysis of Outcome and Prognosis , 2015, Neuroendocrinology.

[43]  B. Scheithauer,et al.  Pituitary carcinoma , 2005, Endocrine.

[44]  M. Rosenfeld,et al.  Transcriptional control of precursor proliferation in the early phases of pituitary development. , 2004, Current opinion in genetics & development.

[45]  Feng Chen,et al.  Neurocytoma of the pituitary gland: A case report and literature review. , 2015, Biomedical reports.

[46]  E. Laws,et al.  Estrogen receptor expression in human pituitary: correlation with immunohistochemistry in normal tissue, and immunohistochemistry and morphology in macroadenomas. , 1994, The Journal of clinical endocrinology and metabolism.

[47]  J. Sheehan,et al.  Stereotactic radiosurgery for acromegaly: outcomes by adenoma subtype , 2015, Pituitary.

[48]  T. Wieland,et al.  Mutations in the deubiquitinase gene USP8 cause Cushing's disease , 2014, Nature Genetics.

[49]  K. Kovacs,et al.  Silent Adenoma Subtype 3 of the Pituitary—Immunohistochemical and Ultrastructural Classification: A Review of 29 Cases , 2005, Ultrastructural pathology.

[50]  P. Chaynes,et al.  Primary sellar neuroblastoma. A new case and review of literature. , 2012, Annales d'endocrinologie.

[51]  W. Couldwell,et al.  Pituitary carcinoma: a review of the literature. , 2004, Neurosurgical focus.

[52]  B. Scheithauer,et al.  Pituitary blastoma , 2008, Acta Neuropathologica.

[53]  R. Lloyd,et al.  WHO classification of tumours of endocrine organs , 2017 .

[54]  E. Laws,et al.  Pit-1 messenger ribonucleic acid is differentially expressed in human pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.

[55]  S. Asa,et al.  The transcription activator steroidogenic factor-1 is preferentially expressed in the human pituitary gonadotroph. , 1996, The Journal of clinical endocrinology and metabolism.

[56]  E. Laws,et al.  Atypical pituitary adenomas: incidence, clinical characteristics, and implications. , 2011, Journal of neurosurgery.

[57]  Antonio Di Ieva,et al.  Aggressive pituitary adenomas—diagnosis and emerging treatments , 2014, Nature Reviews Endocrinology.

[58]  W. Kucharczyk,et al.  Silent subtype 3 pituitary adenomas are not always silent and represent poorly differentiated monomorphous plurihormonal Pit-1 lineage adenomas , 2016, Modern Pathology.

[59]  Z. Qian,et al.  Clinicopathological Features of Growth Hormone-producing Pituitary Adenomas: Difference among Various Types Defined by Cytokeratin Distribution Pattern Including a Transitional Form , 2008, Endocrine pathology.

[60]  S. Kulawonganunchai,et al.  Germline and somatic DICER1 mutations in a pituitary blastoma causing infantile-onset Cushing's disease. , 2014, The Journal of clinical endocrinology and metabolism.

[61]  W. Kucharczyk,et al.  Null Cell Adenomas of the Pituitary Gland: an Institutional Review of Their Clinical Imaging and Behavioral Characteristics , 2015, Endocrine Pathology.

[62]  M. Shichiri,et al.  Differential expression of genes related to drug responsiveness between sparsely and densely granulated somatotroph adenomas. , 2012, Endocrine journal.

[63]  M. Korbonits,et al.  Genetic Aspects of Pituitary Adenomas. , 2017, Endocrinology and metabolism clinics of North America.

[64]  C. Stratakis,et al.  15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas. , 2015, Endocrine-related cancer.

[65]  Michael F. Covington,et al.  Pituicytoma, Spindle Cell Oncocytoma, and Granular Cell Tumor: Clarification and Meta-Analysis of the World Literature since 1893 , 2011, American Journal of Neuroradiology.

[66]  M. Lopes,et al.  Mixed Gangliocytoma-Pituitary Adenoma: Insights on the Pathogenesis of a Rare Sellar Tumor , 2017, The American journal of surgical pathology.

[67]  Xiao-ling Yan.  Null cell adenoma , 2016 .

[68]  B. Scheithauer,et al.  Silent subtype 3 pituitary adenoma: a clinicopathologic analysis of the Mayo Clinic experience , 2009, Clinical endocrinology.

[69]  M. Komada,et al.  The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease. , 2015, The Journal of clinical endocrinology and metabolism.

[70]  Michael Buchfelder,et al.  Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry. , 2007, European journal of endocrinology.

[71]  S. Asa,et al.  Cell type-specific expression of the pituitary transcription activator pit-1 in the human pituitary and pituitary adenomas. , 1993, The Journal of clinical endocrinology and metabolism.

[72]  J. Trouillas,et al.  Cushing's disease and hyperprolactinemia due to a mixed ACTH- and prolactin-secreting pituitary macroadenoma. , 1991, Pathology, research and practice.

[73]  A. Lania,et al.  Genetics of Pituitary Tumors: Focus on G-Protein Mutations , 2003, Experimental biology and medicine.

[74]  Jiawei Shen,et al.  Recurrent gain-of-function USP8 mutations in Cushing's disease , 2015, Cell Research.

[75]  D. Figarella-Branger,et al.  A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up , 2013, Acta Neuropathologica.

[76]  Z. Jaunmuktane,et al.  Plurihormonal pituitary adenoma with concomitant adrenocorticotropic hormone (ACTH) and growth hormone (GH) secretion: a report of two cases and review of the literature , 2013, Acta Neurochirurgica.

[77]  Xiao-ling Yan.  Granular cell tumor of the sellar region , 2016 .

[78]  B. Scheithauer,et al.  Multiple adenomas of the human pituitary. A retrospective autopsy study with clinical implications. , 1991, Journal of neurosurgery.

[79]  D. Okonkwo,et al.  Clinical Characteristics of Silent Corticotrophic Adenomas and Creation of an Internet-accessible Database to Facilitate Their Multi-institutional Study , 2003, Neurosurgery.

[80]  J. Donckier,et al.  Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. , 1997, The Journal of clinical endocrinology and metabolism.